Debora Lucia Seguro Danilovic

Debora Lucia Seguro Danilovic

Auto-generated profile, based on publicly available information

Debora Lucia Seguro Danilovic

Laboratorio de Endocrinologia Celular e Molecular (LIM25), Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, Brazil

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2006 in Osteoporosis International
Verified
Journal Article
Closed access
PDF file
DDD. L. S. Danilovic
D. L. S. Danilovic
PCP. H. S. Correa
P. H. S. Correa
ECE. M. F. Costa
E. M. F. Costa
KMK. F. S. Melo
K. F. S. Melo
BMBerenice Bilharinho Mendonca
Berenice Bilharinho Mendonca
IAI. J. P. Arnhold
I. J. P. Arnhold

1 September 2006 in Fertility and Sterility
Verified
Journal Article
Closed access
MKMirta Knoepfelmacher
Mirta Knoepfelmacher
DDDebora L.S. Danilovic
Debora L.S. Danilovic
RNRubia H.R. Rosa Nasser
Rubia H.R. Rosa Nasser
BMBerenice Bilharinho Mendonca
Berenice Bilharinho Mendonca

28 June 2008 in Clinical Endocrinology
Verified
Journal Article
Closed access
PDF file
DRDaniella Jesus Patrick Carminatti Romanholi
Daniella Jesus Patrick Carminatti Romanholi
MMMarcio Carlos Machado
Marcio Carlos Machado
CPCamila Canteiro Pereira
Camila Canteiro Pereira
DDDebora Seguro Danilovic
Debora Seguro Danilovic
MPMaria Adelaide Albergaria Pereira
Maria Adelaide Albergaria Pereira
LSLuiz Roberto Salgado
Luiz Roberto Salgado

13 October 2016 in PLOS ONE
Verified
Journal Article
Open access
PDF file
DDDebora Lucia Seguro Danilovic
Debora Lucia Seguro Danilovic
BFBruno Ferraz-de-Souza
Bruno Ferraz-de-Souza
AFAmanda Wictky Fabri
Amanda Wictky Fabri
NSNathalie Oliveira Santana
Nathalie Oliveira Santana
MKMarco Aurelio Kulcsar
Marco Aurelio Kulcsar
AHAna Oliveira Hoff
Ana Oliveira Hoff
The increasing incidence of thyroid nodules demands identification of risk factors for malignant disease. Several studies suggested the association of higher TSH levels with cancer, but influence of 25-hydroxyvitamin D (25OHD) is controversial. This study aimed to identify the relationship of thyroid cancer with higher TSH levels and hypovitaminosis D and to evaluate their influence on prognostic characteristics of papillary thyroid carcinomas (PTC). We retrospectively evaluated 433 patients submitted to thyroidectomy for thyroid nodules. Patients were categorized according to quartiles of TSH and 25OHD levels. Clinicopathological features were analyzed. Subjects with thyroid carcinomas were more frequently male and younger compared to those with benign disease. Their median TSH levels were higher and adjusted odds-ratio (OR) for cancer in the highest-quartile of TSH (> 2.4 mUI/mL) was 2.36 (1.36–4.09). Although vitamin D deficiency/insufficiency was prevalent in our cohort (84%), no significant differences in 25OHD levels or quartile distribution were observed between benign and malignant cases. Among 187 patients with PTC, analyses of prognostic features revealed increased risk of lymph nodes metastases for subjects with highest-quartile TSH levels (OR = 3.7, p = 0.029). Decreased 25OHD levels were not overtly associated with poor prognosis in PTC. In this cross-sectional cohort, higher TSH levels increased the risk of cancer in thyroid nodules and influenced its prognosis, particularly favoring lymph nodes metastases. On the other hand, no association was found between 25OHD levels and thyroid carcinoma risk or prognosis, suggesting that serum 25OHD determination may not contribute to risk assessment workup of thyroid nodules.

12 July 2024 in Thyroid®
Verified
Journal Article
Closed access
FPFabián Pitoia
Fabián Pitoia
EAErika Abelleira
Erika Abelleira
ARAlejandro Román-González
Alejandro Román-González
DDDebora L. S. Danilovic
Debora L. S. Danilovic
RSRafael Selbach Scheffel
Rafael Selbach Scheffel
ICInés Califano
Inés Califano
Background: Surgical resection is not always achievable in thyroid cancer patients. Neoadjuvant therapy is rarely used, but recent trends favor multikinase inhibitors or selective tyrosine kinase inhibitors. These aim to reduce tumor volume, enabling previously unfeasible surgeries. Patients and Methods: Consecutive patients with locally advanced malignant thyroid tumors who received systemic therapies with a neoadjuvant intention were included in this retrospective multicenter case series conducted in five Latin American referral centers. Primary outcomes were pre- versus postneoadjuvant response evaluations using the Response Evaluation Criteria in Solid Tumors, feasibility of surgery, and completeness of resection. Secondary outcomes were mortality and status at the last visit. Results: Twenty-seven patients were included in this analysis. Patients with unresectable differentiated thyroid cancer (DTC) or poorly differentiated thyroid cancer (PDTC) received sorafenib ( n = 6) or lenvatinib ( n = 12), those with medullary thyroid cancer (MTC) were treated with vandetanib ( n = 5) or selpercatinib ( n = 1), and those with anaplastic thyroid cancer (ATC) harboring a BRAF V600E mutation ( n = 3) received dabrafenib and trametinib. The median patient age was 66 years (range 12–82), and 52% of the patients were female. In patients with PTC and PDTC, the median reduction in the diameter of the primary tumor was 25% (range 0–100%) after a median of 6 months of treatment. Surgical intervention was performed in 10 (55%) of the patients. Among these, six patients (60%) achieved R0/R1 resection status. Six patients with MTC had a median reduction in tumor diameter of 24.5% (range 1–49) after a median treatment time of 9.5 months. Only one patient receiving selpercatinib, with a tumoral reduction of 25% could undergo surgery, resulting in an R2 resection due to extensive mediastinal extension. Three patients with ATC showed a median tumor diameter reduction of 42% (range 6.7–50) after a median treatment time of 2 months. Two patients underwent surgical intervention and achieved R1 and R2 resection, respectively. Conclusions: While neoadjuvant therapy achieved tumoral responses, surgical resection was feasible in 55% of DTC, 33% of ATC, and 16% of MTC patients, with R0/R1 resection in 26% of the cohort, underscoring the need for patient selection and further research in this area.

7 May 2018 in Archives of Endocrinology and Metabolism
Verified
Journal Article
Open access
PDF file
DDDebora L. S. Danilovic
Debora L. S. Danilovic
GCGilberto Castro
Gilberto Castro
FRFelipe S. R. Roitberg
Felipe S. R. Roitberg
FVFelipe A. B. Vanderlei
Felipe A. B. Vanderlei
FBFernanda A. Bonani
Fernanda A. Bonani
AHAna O. Hoff
Ana O. Hoff
Total thyroidectomy, radioiodine (RAI) therapy, and TSH suppression are the mainstay treatment for differentiated thyroid carcinomas (DTCs). Treatments for metastatic disease include surgery, external-beam radiotherapy, RAI, and kinase inhibitors for progressive iodine-refractory disease. Unresectable locoregional disease remains a challenge, as standard therapy with RAI becomes unfeasible. We report a case of a young patient who presented with unresectable papillary thyroid carcinoma (PTC), and treatment with sorafenib allowed total thyroidectomy and RAI therapy. A 20-year-old male presented with severe respiratory distress due to an enlarging cervical mass. Imaging studies revealed an enlarged multinodular thyroid gland, extensive cervical adenopathy, severe tracheal stenosis, and pulmonary micronodules. He required an urgent surgical intervention and underwent tracheostomy and partial left neck dissection, as the disease was deemed unresectable; pathology revealed PTC. Treatment with sorafenib was initiated, resulting in significant tumor reduction allowing near total thyroidectomy and bilateral neck dissection. Postoperatively, the patient underwent radiotherapy for residual tracheal lesion, followed by RAI therapy for avid cervical and pulmonary disease. The patient's disease remains stable 4 years after diagnosis. Sorafenib has been approved for progressive RAI-refractory metastatic DTCs. In this case report, we describe a patient with locally advanced PTC in whom treatment with sorafenib provided sufficient tumor reduction to allow thyroidectomy and RAI therapy, suggesting a potential role of sorafenib as an induction therapy of unresectable DTC.